AEON BIOTECH AS: årsregnskap 2024 vs 2023
Grew 451% on revenue, stronger earnings, cash halved-plus
approved 2025-05-07; registry 2025-05-17; journal 2025 439866
Summary
What changed
Comparing Årsregnskap 2024 with 2023 for AEON BIOTECH AS. Revenue 20.5k NOK → 113.0k NOK (+451.1%). Net result -668.7k NOK → -207.2k NOK. Equity 75.8k NOK → -131.4k NOK.
On the constructive side: revenue rose; operating result improved; net result improved. Pressures included: equity eroded; cash fell; current ratio dropped below 1×.
Also worth watching: thin equity buffer; cogs fell. All figures are taken from the published annual accounts for AEON BIOTECH AS.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 20.5k NOK to 113.0k NOK (+451.1% YoY). Calculated
-
↑
Operating result improved
Operating result -668.7k NOK → -206.9k NOK (op. margin -3260.7% → -183.1%). Calculated
-
↑
Net result improved
Net result -668.7k NOK → -207.2k NOK (net margin -3260.7% → -183.3%). Calculated
What deteriorated
-
↓
Equity eroded
Book equity 75.8k NOK → -131.4k NOK (equity ratio 86.0% → -362.1%). Calculated
-
↓
Cash fell
Bank deposits 67.6k NOK → 4 965 NOK (-92.7% YoY). Calculated
-
↓
Current ratio dropped below 1×
Current ratio 7.14× → 0.34× — short-term liabilities now exceed liquid/current assets on the published lines. Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is -362.1% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation
-
·
COGS fell
COGS / varekostnad 608.6k NOK → 247.3k NOK (-59.4% YoY). Calculated